Q2 Earnings Estimate for MRKR Issued By Brookline Cap M

Marker Therapeutics, Inc. (NASDAQ:MRKR) – Analysts at Brookline Cap M issued their Q2 2026 earnings estimates for Marker Therapeutics in a report issued on Wednesday, March 18th. Brookline Cap M analyst L. Cann forecasts that the company will post earnings per share of ($0.27) for the quarter. The consensus estimate for Marker Therapeutics’ current full-year earnings is ($0.65) per share.

Marker Therapeutics (NASDAQ:MRKR) last announced its quarterly earnings data on Wednesday, March 18th. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.17. The business had revenue of $1.10 million for the quarter, compared to analyst estimates of $0.68 million. Marker Therapeutics had a negative net margin of 343.03% and a negative return on equity of 80.86%.

Several other equities analysts also recently commented on MRKR. Wall Street Zen upgraded Marker Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, January 3rd. Zacks Research downgraded Marker Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, January 12th. UBS Group restated a “buy” rating on shares of Marker Therapeutics in a research note on Monday, December 8th. HC Wainwright started coverage on Marker Therapeutics in a research report on Monday, December 8th. They set a “buy” rating and a $10.00 price target on the stock. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Marker Therapeutics in a research note on Monday, December 22nd. One analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $11.25.

Marker Therapeutics Stock Up 1.5%

Shares of MRKR stock opened at $1.34 on Friday. The company has a 50 day moving average of $1.59 and a 200-day moving average of $1.30. Marker Therapeutics has a 12-month low of $0.81 and a 12-month high of $4.07. The firm has a market cap of $22.34 million, a P/E ratio of -1.58 and a beta of 1.42.

Institutional Investors Weigh In On Marker Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of MRKR. NewEdge Advisors LLC purchased a new stake in shares of Marker Therapeutics during the fourth quarter worth $222,000. XTX Topco Ltd grew its position in shares of Marker Therapeutics by 166.6% in the fourth quarter. XTX Topco Ltd now owns 58,041 shares of the company’s stock valued at $86,000 after purchasing an additional 36,269 shares in the last quarter. Osaic Holdings Inc. raised its stake in shares of Marker Therapeutics by 16.5% during the 4th quarter. Osaic Holdings Inc. now owns 94,421 shares of the company’s stock valued at $141,000 after purchasing an additional 13,340 shares during the period. Jane Street Group LLC purchased a new stake in Marker Therapeutics during the 4th quarter worth about $60,000. Finally, Renaissance Technologies LLC lifted its holdings in Marker Therapeutics by 16.4% during the 4th quarter. Renaissance Technologies LLC now owns 123,650 shares of the company’s stock worth $184,000 after purchasing an additional 17,400 shares in the last quarter. Institutional investors own 22.39% of the company’s stock.

About Marker Therapeutics

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.